A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer.

ABSTRACT:

Background

Nab-paclitaxel is a novel nanoparticle, albumin-bound, solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (MBC). This study reports clinical benefit and toxicities experienced by women with MBC treated with nab-paclitaxel.

Methods

Women with MBC treated with single-agent nab-paclitaxel between January 2012 and March 2014 were included in this analysis. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity and survival. Clinical benefit was defined as partial or complete response or stable disease (by clinical or radiologic evaluation, or both) at 6 months or more.

Results

Overall response rates (complete or partial responses) were 43% (95

SUBMITTER: Singh RK 

PROVIDER: S-EPMC5649768 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature